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1  | INTRODUC TION
Our innate immune system orchestrates a first and rapid response 
against microbial pathogens and sterile damage. Innate immune cells 
respond to these threats by activation of non-specific germline-en-
coded pattern recognition receptors (PRRs).1 Some PRRs directly bind 
evolutionary conserved moieties from pathogens that are commonly 
referred to as pathogen-associated molecular patterns (PAMPs) or 
respond to danger-associated molecular patterns (DAMPs) that are 
generated or dislocated upon cellular damage. Other PRRs indirectly 
guard against infections by detecting the activity of virulence fac-
tors used by a suite of pathogens to manipulate the host cell machin-
ery in order to survive in a hostile intracellular environment. Toll-like 
receptors (TLRs) and c-type lectin receptors (CLRs) are examples of 
membrane-bound PRRs that survey the extracellular environment 
and the endosomal compartment. Other PRRs are expressed intra-
cellularly or face the cytosolic compartment, such as the nucleo-
tide-binding domain, leucine-rich repeat-containing proteins (NLRs), 
the retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs), ab-
sent in melanoma 2 (AIM2)-like receptors (ALRs) and members of the 
tripartite motif (TRIM) receptors.1
Most PRRs engage signaling pathways that result in extensive 
transcriptional reprogramming of the cell, including upregulation 
of additional PRRs and production of pro-inflammatory cytokines, 
chemokines and type I interferons that orchestrate the early inflam-
matory and host defense responses and help to shape downstream 
activation of adaptive immunity.2 In contrast, a subset of NLRs 
(NLRP3, NLRC4, and NLRP1), ALRs (AIM2), and Pyrin (a TRIM family 
member) regulate innate immune responses at the post-translational 
level by assembling inflammasome complexes.3,4 Although these 
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Abstract
Inflammasomes are macromolecular complexes formed in response to pathogen-
associated molecular patterns (PAMPs) and danger-associated molecular patterns 
(DAMPs) that drive maturation of the pro-inflammatory cytokines interleukin 
(IL)-1β and IL-18, and cleave gasdermin D (GSDMD) for induction of pyroptosis. 
Inflammasomes are highly important in protecting the host from various microbial 
pathogens and sterile insults. Inflammasome pathways are strictly regulated at both 
transcriptional and post-translational checkpoints. When these checkpoints are 
not properly imposed, undue inflammasome activation may promote inflammatory, 
metabolic and oncogenic processes that give rise to autoinflammatory, autoimmune, 
metabolic and malignant diseases. In addition to clinically approved IL-1-targeted bio-
logics, upstream targeting of inflammasome pathways recently gained interest as a 
novel pharmacological strategy for selectively modulating inflammasome activation 
in pathological conditions.
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inflammasome sensors differ in their expression patterns and the 
upstream signaling pathways that regulate their activation, they all 
oligomerize and recruit the adapter molecule apoptosis-associated 
speck-like protein containing a CARD (ASC) to seed a fibrillary struc-
ture named the “ASC speck” that recruits caspase-1 through homo-
typic pyrin-pyrin (PYD-PYD) and CARD-CARD interactions.3,4 These 
inflammasome complexes serve to facilitate proximity-induced auto-
activation of caspase-1, which proceeds to cleave the pro-inflamma-
tory cytokines interleukin (IL)-1β and IL-18 into bioactive, secreted 
cytokines. Besides the amino-terminal CARD domain by which it is 
recruited into inflammasomes, caspase-1 consists of a carboxy-ter-
minal protease domain that harbors the evolutionary conserved cat-
alytic residues in its p20 and p10 subunits.5 Interestingly, naturally 
occurring genetic variants in human caspase-1 that decrease its pro-
tease activity and the levels of IL-1β production have been associ-
ated with the development of autoinflammatory disease in patients.6 
Recent studies in mice expressing a catalytically inactive caspase-1-
C284A mutant suggest that inactive caspase-1 may recruit recep-
tor-interacting protein kinase 2 (RIPK2) to enhance NF-κB-mediated 
IL-6 and TNF-α production.7 Additionally, inflammasome activation 
promotes ASC- and caspase-8-mediated apoptosis in macrophages 
expressing catalytically inactive caspase-1, suggesting that nature 
evolved mechanisms to safeguard inflammatory responses when 
caspase-1 activation is compromised.8
Concomitant with cleavage of IL-1β and IL-18, caspase-1 activa-
tion results in a lytic regulated cell death mode, termed pyroptosis, 
through proteolytic activation of gasdermin D (GSDMD).9-11 Upon 
cleavage, the pore-forming amino-terminal domain of GSDMD in-
serts into the plasma membrane, where it assembles into higher 
order oligomers that perforate the plasma membrane and eventually 
result in osmotic swelling and cell rupture.12-14 GSDMD-mediated 
cell lysis promotes the extracellular release of IL-1β and IL-18 from 
macrophages along with other alarmins such as IL-1α and high mo-
bility group protein B1 (HMGB1) that contribute to shaping innate 
immune and inflammatory responses.9-11,15-18
In this review, we will briefly introduce the different inflam-
masome pathways followed by a discussion of IL-1-targeted biologics 
that are currently approved for the treatment of specific autoinflam-
matory diseases. Finally, we will provide an overview of experimental 
biologics and small molecule inflammasome agonist and antagonist 
therapies that are under development for modulating inflammasome 
activation in inflammatory and malignant diseases.
2  | INFL AMMA SOME SENSORS AND 
THEIR AC TIVATION MECHANISMS
2.1 | NLRP1
The first member of the NLR family shown to form an inflamma-
some is NLRP1.19 Humans encode a single NLRP1 gene, whereas 
mice carry three paralogous genes named Nlrp1a, Nlrp1b, and Nlrp1c. 
The latter is considered a pseudogene, whereas both NLRP1a and 
NLRP1b assemble inflammasomes.20,21 Bacillus anthracis lethal toxin 
(LeTx) specifically activates the NLRP1b inflammasome, while agents 
that selectively engage the NLRP1a inflammasome remain to be dis-
covered. The cytosolic postproline dipeptidyl peptidases (DPP)8 and 
DPP9 suppress activation of human NLRP1 and its murine orthologs 
through mechanisms that are incompletely understood. In agree-
ment, boronic acid peptides such as Val-boroPro (also known as 
Talabostat) that inhibit DPP8/9 as well as several other DPP family 
members, and the DDP8/9-selective inhibitor 1G244 activate human 
NLRP1 and the murine NLRP1b inflammasomes.22-25 Activation of 
human NLRP1 and murine NLRP1b is thought to involve proteaso-
mal degradation of the auto-inhibitory amino-terminal region, which 
enables the recruitment of ASC and caspase-1 to their carboxy-ter-
minal UPA-CARD-containing regions (Figure 1).26,27
A homozygous NLRP1 gain-of-function mutation was recently 
reported to cause an autosomal recessive form of juvenile-onset 
recurrent respiratory papillomatosis in two siblings with mild der-
matologic abnormalities.28 However, dominantly inherited gain-
of-function mutations in human NLRP1 predispose patients to the 
development of Mendelian diseases characterized by skin inflamma-
tion and dyskeratosis named multiple self-healing palmoplantar car-
cinoma (MSPC), NLRP1-associated autoinflammation with arthritis 
and dyskeratosis (NAIAD), and autoinflammation with arthritis and 
dyskeratosis (AIADK).29,30
2.2 | NLRP3
Due to its broad role in anti-microbial immunity and sterile inflam-
mation, NLRP3 is subjected to multilayered regulation at the tran-
scriptional, post-translational, and activation levels. The protein has 
a tripartite domain architecture composed of an amino-terminal 
PYD, a central NACHT domain, and a C-terminal region containing 
leucine-rich repeat (LRR) motifs. The NACHT domain features an (d)
ATP binding pocket with extended Walker A/B motifs that supports 
ATP hydrolysis, a prerequisite for activation of the NLRP3 inflamma-
some.31 In naive macrophages, NLRP3 expression levels are insuf-
ficient to support inflammasome activation, and NLRP3 activation 
therefore first requires a transcriptional priming signal (signal 1) to 
increase NLRP3 protein expression levels (Figure 1).32 Priming may 
additionally involve post-translational modifications such as phos-
phorylation and deubiquitination to license rapid subsequent NLRP3 
activation by signal 2 agents.33-37 Moreover, both the chaperone 
Hsp90 and the cell cycle-regulated kinase NIMA-related kinase 7 
(NEK7) physically interact with and regulate NLRP3 activation, al-
though TAK1-dependent post-translational priming may also license 
NEK7-independent NLRP3 activation in human macrophages.38-42
Signal 2 agents are chemically and structurally diverse, ranging 
from extracellular ATP, microbial pore-forming protein toxins, and 
organic ionophores to fine particulate matter such as silica and uric 
acid crystals. It is therefore thought that NLRP3 senses these agents 
indirectly through their effect on disruption of the plasma membrane, 
and the concomitant efflux of intracellular potassium levels.43-45 
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NLRP3-activating agents such as crystalline monosodium urate (MSU), 
calcium pyrophosphate dehydrate and cholesterol, and protein ag-
gregates like amyloid-β and islet amyloid polypeptide (IAPP) are im-
plicated in the development of inflammatory pathology in patients. 
Correspondingly, a rich body of preclinical studies showed that Nlrp3 
deficiency in mice protects against inflammatory pathology in models 
of gout, pseudogout, atherosclerosis, inflammatory arthritis, non-al-
coholic steatohepatitis (NASH), Alzheimer's disease (AD), and the ex-
perimental autoimmune encephalomyelitis (EAE) model of multiple 
sclerosis.46-54 Of note, NLRP3 inflammasome activation by influenza 
A virus (IAV) infection is regulated by the Z-DNA binding protein 1 
(ZBP1)-containing PANoptosome, a recently identified multi-protein 
complex that senses IAV and controls induction of pyroptosis, apop-
tosis, and necroptosis in IAV-infected cells.55 TAK1 inhibition and a 
host of additional microbial pathogens also induce NLRP3 inflam-
masome-mediated pyroptosis concomitant with induction of necro-
ptosis and extrinsic apoptosis in the targeted cell population, a process 
that was recently coined as PANoptosis.56-59
Moreover, gain-of-function mutations in NLRP3 cause autoso-
mal dominantly inherited autoinflammatory diseases that are col-
lectively named Cryopyrin-Associated Periodic Syndrome (CAPS), 
and which comprise—in increasing order of clinical severity—familial 
F I G U R E  1   Overview of different inflammasome complexes: (From left to right) Engagement of different TLR receptors leads to activation 
of IKKs, which in turn results in activation of NF-κB signaling. Consequently, NF-κB upregulates different pro-inflammatory cytokines such 
as TNF, IL-6, and pro-IL-1β. In addition, NF-κB signaling upregulates NLRP3 expression (priming step). In the activation step of the NLRP3 
inflammasome, diverse stimuli such as nigericin (ionophore), extracellular ATP, and medically relevant crystals (MSU, cholesterol) are sensed 
by NLRP3 and trigger its activation. Given the diversity of stimuli that activate NLRP3, K+ efflux has been proposed as a common mechanism 
for NLRP3 inflammasome activation, although K+ efflux-independent pathways also exist. NEK7 protein is an essential mediator for NLRP3 
activation that acts independently of its kinase activity. NLRP3 recruits the adapter protein ASC and the protease caspase-1, which drives 
maturation of pro-IL-1β and pro-IL-18 into their respective active forms. At the same time, caspase-1 cleaves GSDMD to release GSDMD-N 
that forms GSDMD pores into the plasma membrane and drives pyroptosis, causing the release of various DAMPs such as IL-1β, IL-18, 
IL-1α, and HMGB1. In the non-canonical NLRP3 pathway, intracellular sensing of LPS activates caspase-4/11 (human/mouse) that cleaves 
GSDMD, which induces pyroptosis, consequently activating the NLRP3 inflammasome and IL-1β maturation through K+-efflux. NLRP1 
undergoes auto-catalytic processing in its FIIND domain. Proteasomal degradation of its auto-inhibitory N-terminus is considered a primary 
requirement of NLRP1 inflammasome activation. In rodents, cleavage on the N-terminal part of the NLRP1b protein by anthrax lethal 
toxin or IpaH7.8 allows the C-terminal CARD domain to engage caspase-1 for activation. In addition, mouse NLRP1b and human NLRP1 
are activated by DPP8/DPP9 inhibitors. Activation of the NLRC4 inflammasome requires NAIPs that recognize T3SS inner rod proteins, 
needle proteins, or flagellin. In case of NLRP1b and NLRC4, caspase-1 can directly be recruited independently of the adapter ASC. dsDNA 
of microbial or host origin in the cytosolic compartment activates AIM2, which requires ASC to activate caspase-1. Clostridium difficile toxins 
(TcdA/B) inhibit RhoA GTPases activity, which inhibits PKN1/2-dependent phosphorylation of Pyrin. Consequently, 14-3-3 disengages from 
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cold-induced autoinflammatory syndrome (FCAS), Muckle-Wells 
syndrome (MWS), and neonatal-onset multisystem inflammatory 
disease (NOMID) (also known as chronic infantile neurologic, cuta-
neous, articular syndrome (CINCA)). Mechanistic studies in CAPS 
mouse models and clinical experience with IL-1-targeted therapies 
both suggest that excessive IL-1β production is the key mediator of 
systemic inflammatory pathology in CAPS, with evidence for addi-
tional roles of IL-18 and pyroptosis.18,60,61
2.3 | NLRC4
The NLRC4 inflammasome assembles upon physical binding of 
bacterial flagellin and type III secretion system (T3SS) components 
by NLR family apoptosis inhibitory proteins (NAIPs). Human NAIP 
recognizes the T3SS needle protein, whereas murine NAIP5 and 
NAIP6 detect flagellin, and NAIP1 and NAIP2 detect needle and 
rod proteins of T3SS, respectively (Figure 1).62-64 Gain-of-function 
mutations in NLRC4 cause potentially lethal periodic fever syn-
dromes that are characterized by high circulating IL-18 levels and 
increased risk for the development of macrophage activation syn-
drome (MAS).65,66
2.4 | AIM2
The ALR family member AIM2 mediates inflammasome responses 
upon recognition of double-stranded DNA (dsDNA) in the cytosol of 
murine macrophages. It does not appear to select for specific nucleic 
acid sequences and the detected dsDNA fragments may originate 
from the host's nuclear genome, or may originate from infection 
with specific viruses (vaccinia virus and cytomegalovirus) or bacte-
ria (Francisella tularensis and Listeria monocytogenes) (Figure 1).67-71 
GTPases of the guanylate-binding proteins (GBP) family mediate 
activation of the AIM2 inflammasome by F. tularensis and other 
bacterial pathogens.72,73 The AIM2 inflammasome has also been 
shown to promote irradiation-induced hematopoietic failure and 
gastrointestinal syndrome in response to genomic dsDNA breaks in 
mice.74 Notably, the NLRP3 inflammasome promotes secretion of 
IL-1β in human primary monocytes following recognition of cytosolic 
dsDNA by the cGAS-STING pathway.75 This may explain why con-
trary to other inflammasome sensors, gain-of-function mutations in 
AIM2 have not been reported to cause monogenic autoinflammatory 
disorders in patients.
2.5 | Pyrin
The Pyrin inflammasome indirectly senses inhibition of RhoA 
GTPase activity by Clostridium difficile toxin A (TcdA) and toxin B 
(TcdB) and other bacterial toxins.76-78 Pyrin phosphorylation (at 
S208/S242 in human Pyrin; S205/S241 in murine Pyrin) keeps the 
protein in an inactive state in naïve macrophages.77,79 RhoA GTPase 
inhibition results in dephosphorylation of Pyrin, releasing it from 
14-3-3 proteins and allowing ASC recruitment and subsequent cas-
pase-1 activation (Figure 1). In addition, microtubules are required 
for inflammasome activation downstream of Pyrin dephosphoryla-
tion.77,78 Gain-of-function mutations in the MEFV gene that encodes 
Pyrin cause Familial Mediterranean Fever (FMF), a monogenic au-
toinflammatory disease that affects an estimated 150,000 patients 
worldwide.60 FMF patients present with recurrent fevers associated 
with serositis and may develop serum amyloid A (SAA) amyloidosis 
if colchicine therapy is not initiated in time. Notably, disease-pene-
trant FMF mutations were recently shown to render Pyrin inflamma-
some activation independent of microtubules.78,80
2.6 | The non-canonical inflammasome
Whereas caspase-1 is the central effector protease in canoni-
cal inflammasome pathways, caspases 4 or 5 in humans, and the 
orthologous caspase-11 in rodents, exert this role in the non-
canonical inflammasome pathway that is engaged upon cytosolic 
detection of lipopolysaccharides (LPS)—a major component of the 
outer membrane of Gram-negative bacteria.81-86 These inflamma-
tory caspases cleave GSDMD to induce pyroptosis, and the result-
ing potassium efflux is thought to drive secondary activation of the 
NLRP3 inflammasome (Figure 1).10,81,85,86 Inhibition of the non-
canonical inflammasome pathway has gained considerable traction 
as a potential therapeutic strategy in Gram-negative infections and 
sepsis.9,12,82,86-89
3  | IL-1-TARGETED THER APIES IN THE 
CLINIC
Therapeutic targeting of IL-1 family cytokines, and IL-1β in particu-
lar, has gained significant traction due to its central role in a host of 
autoinflammatory diseases.90,91 Moreover, results from both clinical 
trials and preclinical studies implicate IL-1β in a suite of metabolic, 
malignant, and neurodegenerative diseases.90-92 IL-1β is a highly in-
flammatory and pyrogenic cytokine, and its production and activ-
ity are tightly regulated. Cells of the myeloid lineage—the primary 
source of IL-1β in the body—do not express IL-1β in the absence of 
inflammatory cues, and first need to transcriptionally upregulate its 
production in the context of infection or tissue damage. Rather than 
being secreted through the conventional secretory pathways that 
govern secretion of most other cytokines, activated myeloid cells 
produce IL-1β as a biologically inert precursor (proIL-1β) that is stored 
in the cytosol.93 It gains biological activity following caspase-1-medi-
ated removal of its amino-terminal pro-peptide. Once released into 
the extracellular space, mature IL-1β binds to IL-1 receptor 1 (IL-1R1) 
on effector cells, which promotes heterodimerization of the receptor 
with IL-1R accessory protein (IL-1RAcP) and the subsequent recruit-
ment of intracellular signaling components such as myeloid differ-
entiation primary response gene 88 (MyD88). This process initiates 
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a signaling cascade ultimately resulting in the activation of NF-κB 
and mitogen-activated protein kinase (MAPK) signaling (Figure 2). 
Because of its extensive functions and potency, IL-1 activity in the 
extracellular environment is further regulated by two mechanisms. 
Firstly, the IL-1R antagonist (IL-1Ra) binds to IL-1R1 to block bind-
ing of IL-1α and IL-1β to IL-1R1. Binding of IL-1Ra to IL-1R1 hampers 
the heterodimerization with IL-1RAcP, which prevents initiation of 
intracellular signaling.94 Secondly, the decoy receptor IL-1R type II 
(IL-1R2) that lacks the cytoplasmic TIR domain also binds to IL-1α and 
IL-1β, thereby preventing IL-1 signaling.95
Dependent on the cell type, IL-1 signaling will result in the pro-
duction of pro-inflammatory cytokines, such as TNF-α, IL-8, and IL-6; 
and chemokines that stimulate the attraction of macrophages and 
other immune cells, such as monocyte chemoattractant protein 1 
(MCP1) and the neutrophil attractant chemokines CXCL1 and MIP-
2. Moreover, IL-1β is a potent driver of IL-6-dependent production 
of acute phase proteins in hepatocytes, of which C-reactive protein 
(CRP) and SAA are two major representatives.96 In addition to its cen-
tral role in innate immune and inflammatory responses, IL-1β drives 
polarization of CD4+ T cells toward T-helper type (Th) 1 and Th17 
F I G U R E  2   IL-1 and IL-18 signaling and its modulation by therapeutic agents: (Left) Engagement of IL-1 and IL-18 receptors by IL-1α, 
IL1β, and IL-18, respectively, leads to the cytosolic recruitment of the TIR domain-containing adapter MyD88. Subsequently, MyD88 binds 
to the IRAK kinases IRAK1/2/4, which associate with the E3-ubiquitin ligase TRAF6. This allows dissociation of IRAK kinases and TRAF6 
from the receptor complex and results in the polyubiquitination of the kinase TAK-1, which leads to the phosphorylation of IKKs. In turn, 
IKKs phosphorylate and degrade IκB, subsequently inducing the upregulation of NF-κB target genes and the release of pro-inflammatory 
cytokines. To maintain the balance of IL-1 signaling, extracellular IL-1Ra competitively inhibits the binding of active IL-1β and IL-1α to 
IL-1R1. Furthermore, the decoy receptor IL-1R2 binds to IL-1β and IL-1α and inhibits IL-1 signaling. Similarly, IL-18 signaling is regulated by 
the inhibitory activity of IL-18BP that binds IL-18 and prevents its interaction with its cell surface receptors. (Right) Three biologic agents 
targeting IL-1 signaling have been approved by the FDA. As a recombinant form of the IL-1Ra, anakinra competes with IL-1β and IL-1α for 
binding to IL-1R1. The human anti-IL-1β monoclonal antibody canakinumab specifically binds and neutralizes IL-1β to prevent its interaction 
with IL-1R1. Rilonacept is a soluble decoy receptor, which consists of the extracellular domains of IL-1R1 and IL-1RAcP, and binds and 
neutralizes both IL-1β and IL-1α. Similar to IL-1 blocking agents, the recombinant IL-18BP, tadekinig alfa, and the human anti-IL-18 monoclonal 
antibody, GSK1070806, bind to IL-18 and inhibit the interaction of IL-18 to its cell surface receptors. Both IL-18 blockers are currently under 
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cells, and induces expansion and differentiation of antigen-specific 
CD8+ T cells.97,98 IL-1β has been attributed a largely beneficial role 
in resolving acute inflammation. However, several autoinflammatory 
syndromes are driven by excessive or chronically dysregulated IL-1 
signaling, and IL-1-targeted biologics have proven highly effective 
in treating inflammasomopathies.60 Three biologic anti-IL-1 agents 
are currently approved for clinical use: anakinra, canakinumab, and 
rilonacept (Figure 2).
Anakinra is a nonglycosylated recombinant version of human 
IL-1Ra, and functions as a competitive inhibitor of both IL-1α and 
IL-1β for binding to IL-1R1. It has a good safety profile, but its 
short half-life of 4-6 hours makes daily subcutaneous injections 
necessary to maintain high target engagement levels. Anakinra 
was initially approved for the treatment of rheumatoid arthritis 
with methotrexate in patients that failed treatment on methotrex-
ate alone, but these patients are nowadays prioritized to TNF-
blocking agents. Anakinra is nowadays primarily used to treat 
CAPS and colchicine-resistant FMF.60 Recent clinical studies also 
support its efficacy in gout showing that the drug is equally effec-
tive in relieving pain associated with acute gout flares compared 
to the standard care of treatment.99 A consensus guideline issued 
in 2012 also recommended anakinra as a treatment for Schnitzler's 
syndrome, an autoinflammatory disorder with CAPS-like symp-
toms that include urticarial, periodic fever and joint and bone pain. 
Moreover, in a small multicentre, open-label, randomized clinical 
trial that compared anakinra with a host of TNF-α blockers, IL-1 in-
hibition with anakinra also proved effective in improving glycemic 
and inflammatory parameters in patients affected with rheuma-
toid arthritis and type 2 diabetes.100
Canakinumab is a human monoclonal antibody with an ex-
tended half-life of 26 days that specifically binds and neutralizes 
IL-1β. It has been approved by the FDA for the treatment of CAPS. 
Canakinumab is also being used for treating autoinflammatory 
diseases such as FMF, TNF receptor-associated periodic syn-
drome (TRAPS) and hyperimmunoglobulin D syndrome (HIDS)/
mevalonate kinase deficiency (MKD), systemic juvenile idiopathic 
arthritis, and adult onset Still's disease.101 More recently, canak-
inumab was evaluated in the Canakinumab Anti-inflammatory 
Thrombosis Outcome Study (CANTOS) (ClinicalTrials.gov 
Identifier: NCT01327846). This multi-center, randomized, dou-
ble-blind phase 3 trial involved more than 10,000 atherosclero-
sis patients with previous myocardial infarction and a persistent 
pro-inflammatory response, defined by circulating levels of the 
acute phase protein CRP of 2 mg/L or higher.102 High sensitivity 
CRP measurements are approved as a clinical biomarker of cardio-
vascular risk, and CANTOS was designed to evaluate the therapeu-
tic potential of canakinumab in reducing the risk of cardiovascular 
events and secondary stroke in this cohort.103 Notably, results 
from the study showed that IL-1β inhibition with canakinumab re-
duced serum levels of CRP in a subset of patients. Moreover, a 
25% reduction in major adverse cardiovascular events (MACE) and 
31% reduction in cardiovascular mortality and all-cause mortal-
ity was observed in patients who achieved CRP levels lower than 
2 mg/L, whereas no significant benefit was observed in patients 
that retained CRP levels of 2 mg/L or above on canakinumab.103 
In a separate analysis of the CANTOS cohort, the investigators 
detected a remarkable dose-dependent reduction in the incidence 
of lung cancer and lung cancer-associated mortality with a relative 
risk reduction of 67% for lung cancer (HR 0.33 [95% CI: 0.18-0.59]) 
and 77% for lung cancer mortality (HR 0.23 [95% CI: 0.10-0.54]) 
in patients receiving a 300 mg dose of canakinumab every three 
months.104 These exploratory results suggest that IL-1β neutral-
ization may contribute importantly to intercepting the health tra-
jectory of lung cancer patients and warrant further confirmation 
in independent studies.
A third clinically approved IL-1-targeted therapy for the treat-
ment of CAPS is rilonacept or IL-1 Trap.105 Rilonacept is a human 
dimeric fusion protein consisting of the extracellular domains of IL-
1R1 and IL-1RAcP fused to the Fc fragment of IgG. It functions as a 
soluble decoy receptor that prevents binding of both IL-1α and IL-1β 
to the IL-1R1 (Figure 2). This chimeric protein has a half-life of ap-
proximately 1 week, bridging those of anakinra and canakinumab. 
Rilonacept also proved effective in controlling symptoms in a cohort 
of patients suffering from Schnitzler's syndrome (ClinicalTrials.gov 
Identifier: NCT01045772).106
4  | CLINIC AL E VALUATION OF 
E XPERIMENTAL IL-18-TARGETED 
THER APIES
Although proIL-18 is constitutively expressed in myeloid cells, pro-
duction of bioactive IL-18—akin to IL-1β—requires caspase-1-medi-
ated cleavage following inflammasome activation. Once secreted 
into the extracellular environment, binding of IL-18 to IL-18 receptor 
α (IL-18Rα) and IL-18 receptor β (IL-18Rβ) results in downstream ac-
tivation of inflammatory signaling in effector cells. Given its pleio-
tropic immune roles, several mechanisms exist that tightly regulate 
IL-18 activity in the extracellular milieu.60,94 One such regulatory 
mechanism that is being exploited for diagnosis and therapy of 
patients is the neutralization of IL-18 by the natural IL-18 binding 
protein (IL-18BP), which precludes binding of IL-18 to its cognate re-
ceptors (Figure 2).
Given that the expression ratio of IL-18 and IL-18BP is often 
disturbed in inflammatory diseases, circulating levels of IL-18BP-
unbound IL-18 (free IL-18) have been proposed as a biomarker for 
disease activity in adult onset Still's disease and systemic-onset ju-
venile idiopathic arthritis.107,108 Moreover, a recombinant version 
of human IL-18BP named “tadekinig alfa” demonstrated a favorable 
safety profile with early signs of efficacy in a recent phase II clin-
ical trial of patients with adult onset Still's disease (ClinicalTrials.
gov Identifier: NCT02398435).109 Based on promising data showing 
successful treatment of life-threatening inflammation in an NLRC4-
MAS patient 110, the therapeutic potential of anti-IL-18 therapy 
with tadekinig alfa is currently being investigated in a single-arm, 
open-label phase 3 trial in patients afflicted with NLRC4-MAS or 
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autoinflammation due to monogenic XIAP mutations (ClinicalTrials.
gov Identifier: NCT03113760) given that both syndromes feature 
high circulating IL-18 levels.
GSK1070806 is another biologic that was developed to 
neutralize IL-18-mediated inflammation. Unlike tadekinig alfa, 
GSK1070806 is a recombinant human IL-18-neutralizing an-
tibody with an extended half-life in circulation. It is currently 
being tested in a phase 2 clinical study for the treatment of pa-
tients with moderate to severe Crohn's disease (ClinicalTrials.gov 
Identifier: NCT03681067) (Figure 2). If proven effective, these 
clinical studies may lay the foundation to expand the use of IL-
18-inhibiting biologics to additional autoinflammatory and au-
toimmune diseases and expand our understanding of how IL-18 
promotes destructive and potentially life-threatening inflamma-
tion in patients.
5  | GOING UPSTRE AM: POTENTIAL 
BENEFITS OF INHIBITING INFL AMMA SOME 
COMPONENTS
IL-1- and IL-18-targeted biologics have dramatically improved thera-
peutic outcomes for patients suffering from a subset of autoinflam-
matory diseases, but these protein-based products require patients 
to subject themselves to frequent subcutaneous injections. More 
importantly, chronic suppression of a key arm of the innate immune 
system inevitably comes with an increased risk for serious infec-
tions. Clinical experience with canakinumab and anakinra provides 
comforting real-world evidence that the risk of Mycobacterium 
tuberculosis reactivation and tuberculosis development is signifi-
cantly lower with IL-1-targeted biologics compared to TNF-α inhibi-
tors, but it is evident that chronic IL-1 blockade does increase risk 
of opportunistic infections of the upper airways along with some 
evidence of increased urinary tract infections with Escherichia coli 
and Streptococci.102,111 Additional adverse events that are associated 
with chronic IL-1 inhibition include neutropenia, low platelet counts, 
headaches, abdominal pain, diarrhea, urticarial lesions, and inflam-
mation at the site of injection.100-102
Therapies acting upstream of IL-1β secretion might show an im-
proved safety and efficacy profile because selective inflammasome 
inhibition would still allow IL-1-driven host defense through non-tar-
geted inflammasomes, for example, when the patient faces an acute 
infection, while preventing chronic inflammatory pathology that 
originate from the silenced inflammasome. At the same time, se-
lective inflammasome targeting may increase therapeutic potency 
through the simultaneous blockade of IL-1β, IL-18 and by preventing 
pyroptosis-mediated release of DAMPs such as IL-1α, HMGB1, and 
ATP. This notion is supported by empirical evidence from a host of 
mouse disease models that point to GSDMD-driven pyroptosis as 
the key driver of inflammasome-mediated pathology.17,18,21,61,112,113 
Finally, small molecule inflammasome inhibitors that can be dosed 
orally would relief patients from the need of lifelong injections. 
Hence, a suite of tool compounds and natural compounds have 
been reported to inhibit inflammasome activation in recent years, 
and some molecules are currently being evaluated in early clinical 
studies.
6  | THE QUEST FOR POTENT AND 
SELEC TIVE NLRP3 INHIBITORS
A vast body of studies has implicated the NLRP3 inflammasome in a 
host of inflammatory, metabolic, and neurodegenerative diseases, 
rendering this pathway an attractive target for pharmacological 
modulation across therapeutic areas.60,91,92,114 The first demon-
stration that selective pharmacological inhibition of the NLRP3 in-
flammasome is feasible arrived in 2009 with the demonstration that 
the sulfonylurea-containing compound glyburide inhibited NLRP3-
induced pyroptosis and IL-1β secretion without affecting activation 
of the NLRC4 and NLRP1b inflammasomes.115 The half-inhibitory 
concentration (IC50) of glyburide is in the low μM range, whereas 
the related diarylsulfonylurea compound MCC950/CRID3 inhibits 
NLRP3 activation with nM potency.116 Like glyburide, MCC950/
CRID3 exerts high target selectivity as it inhibits Nlrp3 activation 
without interfering with the AIM2, NLRC4, Pyrin, and NLRP1b in-
flammasomes, or altering TLR4-induced cytokine secretion.78,116 
More recently, MCC950/CRID3 and related tool compounds were 
shown to directly target the NACHT domain of NLRP3 in the vicin-
ity of its ATP/dATP binding pocket, and they represent the most 
potent tool compounds that are currently available for selective 
NLRP3 inflammasome inhibition in human cells and preclinical ro-
dent studies.117-119 Consequently, MCC950/CRID3-mediated inhi-
bition of NLRP3 has shown beneficial effects in mice and other 
preclinical species that have been subjected to disease models, 
among which models of atherosclerosis, myocardial infarction, 
colitis, and skin and airway inflammation.47,116,120-123 Interestingly, 
MCC950/CRID3 and related diarylsulfonylurea compounds may 
be substantially less effective in inhibiting CAPS-related NLRP3 
mutants because in vivo MCC950/CRID3 concentrations that po-
tently inhibited NLRP3-driven inflammation in wildtype mice were 
shown to be ineffective in two in vivo mouse models of CAPS 
disease.119 Concordantly, MCC950/CRID3-derived photoaffinity 
probes labeled the NACHT domain of wildtype NLRP3, but not 
CAPS-associated NLRP3 mutants.119 These results raise the possi-
bility that MCC950/CRID3-based therapies may need to be dosed 
at higher concentrations in CAPS patients to effectively treat in-
flammatory pathology than is needed to curb inflammatory pathol-
ogy driven by wildtype NLRP3.
In addition to inflammatory disease, MCC950/CRID3 also im-
proved clinical and molecular disease markers in models of neu-
rodegenerative disease such as Parkinson's disease, Alzheimer's 
disease, and the EAE model of multiple sclerosis.52,92,114,124 While 
EAE is associated with breakdown of the blood-brain barrier and 
enhanced vascular permeability,125 it is currently unclear whether 
MCC950/CRID3 also crosses the blood-brain barrier in Alzheimer's 
and Parkinson's disease models to reach clinically relevant 
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concentrations in the central nervous system, or whether it damp-
ens neuroinflammatory pathology indirectly in these models by 
modulating NLRP3 activity in the periphery.
Based on these promising results, several MCC950/CRID3 ana-
logs are currently being developed for clinical applications. Two such 
NLRP3 antagonists, namely IZD334 (ClinicalTrials.gov Identifier: 
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NCT04086602) and Inzomelid (ClinicalTrials.gov Identifier: 
NCT04015076), have recently completed early clinical testing to as-
sess the safety, tolerability, and pharmacological properties of the 
drugs in healthy adult participants and to obtain first evidence of 
clinical efficacy in adult CAPS patients (Figure 3). As a secondary 
outcome, these studies analyzed NLRP3 activity in stimulated whole 
blood and monitored clinical symptoms in adult CAPS patients.
Several other small molecule NLRP3 inhibitors have been 
reported, although the potency and selectivity profile of most 
is less stringent than that of MCC950/CRID3. For instance, Bay 
11-7082 and parthenolide are anti-inflammatory compounds 
that inhibit ATPase activity of NLRP3 and also interfere with 
NF-κB-mediated cytokine production.126 Moreover, partheno-
lide was shown to be a direct inhibitor of recombinant caspase-1 
in vitro126; and Bay 11-7082 and parthenolide were recently 
also reported to bind and inhibit GSDMD.127 These molecules 
therefore appear less suitable for clinical development as 
NLRP3-targeted therapies given the risks associated with broad 
immunosuppression.
The tryptophan derivative tranilast also inhibits NLRP3 by direct 
binding to its NACHT domain (Figure 3).128 This molecule demon-
strated therapeutic efficacy in mouse models of NLRP3-driven 
gouty arthritis and CAPS. In addition, tranilast blunted spontaneous 
caspase-1 activation and IL-1β release from isolated synovial fluid 
mononuclear cells of arthritis patients.128 Since its identification 
in 1982 as an anti-allergic agent that suppresses histamine release 
from mast cells, tranilast has been associated with a growing list 
of anti-inflammatory effects, including suppression of TGF-β, NF-
κB, and MAPK signaling (reviewed in 129), suggesting that it may 
not solely inhibit inflammation by suppressing NLRP3 activation. 
However, considering its clinical safety, tolerability, and efficacy 
profile in different indications, tranilast is currently being evaluated 
in a phase 2 open-label clinical trial for efficacy and safety in CAPS 
patients (ClinicalTrials.gov Identifier: NCT03923140).
The β-sulfonyl nitrile compound OLT1177 also was shown to 
inhibit NLRP3-mediated IL-1β release from stimulated PBMCs 
of CAPS patients and primary human neutrophils (Figure 3).130 
Studies in mice suggest additional NLRP3-independent anti-in-
flammatory mechanisms of actions for the compound, but in a 
phase 1 clinical trial, OLT1177 showed a good pharmacokinetic 
profile in healthy individuals with long half-life and no hemato-
logical or organ toxicity at any of the tested doses.130 A recently 
completed phase 2 proof of concept study suggests that OLT1177 
may have significant anti-inflammatory activity in patients suffer-
ing from acute gout.131
CY-09 is an analog of a cystic fibrosis transmembrane conduc-
tance regulator (CFTR) channel inhibitor that was found to inhibit 
the NLRP3 inflammasome with μM IC50 values without affecting 
NLRP3 priming.132 Unlike the parental molecule, CY-09 failed to in-
hibit CFTR activity and was shown to specifically target the ATPase 
activity of NLRP3 by binding at the walker A motif in the central 
NACHT domain (Figure 3). Concordantly, CY-09 significantly de-
creased serum levels of IL-1β and neutrophil influx in a murine model 
of peritoneal MSU-induced inflammation, and it protected mice from 
neonatal lethality upon in vivo expression of an MWS-associated 
NLRP3 mutant.132
3,4-methylenedioxy-β-nitrostyrene (MNS), a known inhibitor 
of tyrosine kinases, emerged as a hit for NLRP3 from a focused ki-
nase inhibitor library screen.133 It interferes with NLRP3's ATPase 
activity by binding to the central NACHT and carboxy-terminal LRR 
domains of NLRP3 (Figure 3). The acrylamide derivative INF58 irre-
versibly inhibits NLRP3 by covalently modifying Cys residues in its 
target protein. It was shown to inhibit ATPase activity of human re-
combinant NLRP3 and IL-1β release from primary and immortalized 
macrophages.134
Unlike the previously mentioned synthetic molecules, oridonin 
is a natural compound derived from the medicinal plant Rabdosia ru-
bescens. It was shown to inhibit NLRP3 activation by preventing the 
interaction between NLRP3 and NEK7 through covalent binding to 
Cys279 in the NACHT domain of NLRP3 (Figure 3). Furthermore, 
oridonin inhibited IL-1β production in NLRP3-dependent mouse 
models of peritonitis and gouty arthritis.135 However, in addition 
to interfering with NLRP3 inflammasome activation, the molecule 
was shown to inhibit inflammation through several additional mech-
anisms of action, including inhibition of NF-κB and MAPK signaling, 
induction of apoptosis, cell cycle arrest and it was also shown to have 
anti-tumor activity.136-139
In addition to molecules with a direct mechanism of action on 
NLRP3, several molecules that inhibit NLRP3 activation indirectly by 
targeting post-translational modifications have also been reported. 
Two recent studies suggest that acetylation of the amino-termi-
nal PYD in NLRP3 is required for recruitment of ASC and optimal 
downstream inflammasome signaling.140,141 The authors go on to 
show that this mechanism was specific to NLRP3 because the AIM2 
and NLRC4 inflammasomes were not affected by inhibition of this 
post-translational modification. Furthermore, c-Jun N-terminal ki-
nase 1 (JNK1)-mediated phosphorylation of NLRP3 Ser194 was 
shown to be a critical priming event that supports optimal NLRP3 
activation.34 Although selective modulation of NLRP3 activation 
through these indirect mechanisms may prove challenging, potent 
pharmacological inhibitors that target specific post-translational 
events might provide additional avenues to suppress NLRP3-driven 
inflammation.
7  | TARGETING ALTERNATIVE 
INFL AMMA SOME PATHWAYS
In contrast to the breath of molecules that inhibit the NLRP3 
inflammasome, selective small molecule inhibitors of other in-
flammasome sensors remain to be discovered. Nevertheless, the 
microtubule polymerization inhibitor colchicine selectively inhib-
its activation of the Pyrin inflammasome in murine macrophages 
and human monocytes.78 Interestingly, however, disease-pen-
etrant FMF mutations in MEFV render activation of the Pyrin 
inflammasome resistant to colchicine inhibition. This feature 
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appeared highly specific for FMF-associated mutations and was 
recently leveraged to develop a functional diagnostic assay for 
rapidly stratifying FMF patients.80 Significantly lower doses of 
colchicine are being used in the clinic since the 1970' to effec-
tively control FMF symptoms, but the therapeutic mode of action 
of colchicine in FMF and gout patients remains a mystery.
Human NLRP1 and its murine paralogs Nlrp1a and Nlrp1b are 
unique in their requirement for proteasomal degradation to promote 
inflammasome activation.26,27,142,143 In line herewith, proteasome 
inhibitors such as MG-132 and bortezomib selectively inhibit activa-
tion of the NLRP1 inflammasome without modulating activation of 
NLRP3 and other inflammasome pathways.
8  | SELEC TIVE C A SPA SE-1 INHIBITION—A 
RE AL CHALLENGE
As the protease that matures IL-1β and the common denomina-
tor of all canonical inflammasome pathways, developing clini-
cal-grade molecules that selectively inhibit caspase-1 protease 
activity has been a focal effort of the pharmaceutical industry for 
many years. Like in other caspases, the evolutionary conserved 
Cys285 in the active site of caspase-1 employs a nucleophilic 
attack. An electrophilic warhead that reacts with and inhibits 
Cys285 is therefore one of the strategies used by reversible (al-
dehyde-containing) and non-reversible (ketone-based) tetrapep-
tide inhibitors to inhibit caspase-1.144 Nonetheless, due to their 
toxic byproducts, poor stability, solubility and selectivity, tetra-
peptide-based inhibitors are not suitable for therapeutic appli-
cation.145 Fully synthetic peptide-mimetic prodrugs such VX-740 
(pralnacasan) and VX-765 (belnacasan) were generated to over-
come the toxicity and low bioavailability issues associated with 
peptidic caspase inhibitors. These prodrugs are metabolically 
converted in the cytosol by esterase activity to, respectively, 
VRT-18858 and VRT-043198, both of which act as reversible in-
hibitors of caspase-1 and the related inflammatory caspases 4 
and 5 (Figure 3).146,147
VX-740 was shown to reduce joint damage in two mouse 
models of osteoarthritis and it attenuated dextran sulfate so-
dium (DSS)-induced colitis.147,148 However, a phase 2 clinical trial 
with VX-740 in rheumatoid arthritis patients was discontinued 
after hepatotoxicity was observed in long-term follow-up ani-
mal studies.145 VX-765, on the other hand, was shown to reduce 
acute seizures and chronic epileptic activity in two mouse mod-
els of epilepsy, and it significantly suppressed the production of 
inflammatory mediators in models of rheumatoid arthritis and 
skin inflammation.149 It was also shown to improve cognition 
in a mouse model of Alzheimer's disease by inhibiting amyloid 
beta deposition and neuroinflammation.150 Although VX765 has 
a favorable safety profile, a phase 2 clinical trial in patients with 
treatment-resistant partial epilepsy failed to reach its primary 
endpoints (ClinicalTrials.gov Identifier: NCT01501383).151 These 
challenges have spurred investigators to refocus efforts on 
inhibiting inflammasome sensors that act upstream of caspase-1, 
and more recently, on targeting the pyroptosis effector GSDMD.
9  | GSDMD—THE NE W KID ON THE 
BLOCK
GSDMD is expressed as a soluble, inactive precursor protein that 
consists of an amino-terminal pore-forming domain (GSDMD-N) and 
a carboxy-terminal auto-inhibitory domain (GSDMD-C) that are sep-
arated by a flexible interdomain linker.9,10 Inflammatory caspases (ie, 
caspases 1, 4, and 5 in humans; and caspases 1 and 11 in mice) cleave 
GSDMD in the interdomain linker, thus allowing GSDMD-N to trans-
locate into the inner plasma membrane leaflet. It subsequently as-
sembles into oligomers that pinch both plasma membrane leaflets to 
form large GSDMD pores allowing osmotic swelling and pyroptotic 
cell death.152 In addition to pyroptosis, GSDMD was shown to induce 
the release of web-like chromatin structures called “neutrophil ex-
tracellular traps” from neutrophils as part of a specialized cell death 
mode known as NETosis.153,154
Mice deficient in GSDMD are significantly protected against LPS-
induced endotoxic shock and lethality.9 Moreover, GSDMD was shown 
to play a critical role in driving IL-1β-dependent inflammatory pathol-
ogy in mouse models of CAPS and FMF.17,18 Moreover, preventing 
GSDMD activation in peripheral myeloid cells was recently shown to 
protect mice from neuroinflammation and demyelination in the EAE 
model of multiple sclerosis.113 Another recent study found a key role 
for GSDMD in non-alcoholic steatohepatitis in humans and mice.155
These findings raised significant interest in the discovery of 
GSDMD-targeted drugs, and several molecules have already been 
reported to inhibit GSDMD-mediated pore formation. The alkylat-
ing compound necrosulfonamide (NSA) binds directly to full-length 
GSDMD via Cys191, thereby preventing GSDMD-N dimers from 
assembling higher order oligomers that drive pyroptotic pore for-
mation and cell lysis (Figure 3). NSA similarly modifies a reactive Cys 
residue in mixed lineage kinase domain-like pseudokinase (MLKL), 
thus preventing its recruitment to RIPK3 and inhibiting induction of 
another lytic cell death mode termed necroptosis.156,157
Disulfiram and Bay 11-7082 were recently discovered in a screen 
for inhibitors of GSDMD using a fluorogenic liposome leakage 
assay.127 Notably, both molecules inhibited GSDMD by covalently 
modifying the GSDMD Cys191 residue that is also targeted by NSA 
(Figure 3).127 As discussed above, Bay 11-7082 is a potent inhibitor of 
inhibitor κB kinase (IKK) that also targets NLRP3 and caspase-1.126 
As an inhibitor of acetaldehyde dehydrogenase, disulfiram is used in 
the clinic for treating alcohol addiction.158 Disulfiram also inhibited 
TLR-induced priming at higher concentrations, and both disulfiram 
and Bay 11-7082 attenuated ASC speck formation and the protease 
activities of caspases 1 and 11.126,127,159 Disulfiram was shown to in-
hibit pyroptosis in human and murine myeloid cells with µM potency, 
and it prevented secretion of IL-1β from these cells.127 When dosed 
intraperitoneally in LPS-challenged mice, it significantly delayed le-
thality at a concentration of 50 mg/kg.127
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LDC7559 emerged as a direct inhibitor of GSDMD from a small 
molecule screen for inhibitors of phorbol ester-induced NETosis in 
human neutrophils (Figure 3).153. Whereas disulfiram, NSA and Bay 
11-7082 inhibit GSDMD through covalent modification of Cys191, 
the mechanism of action of LDC7559 is unclear. LDC7559 inhibited 
pyroptosis by the NLRP3 and AIM2 inflammasomes,153 but other 
findings suggest that it may lack activity on recombinant GSDMD 
in the liposome leakage assay.160 Future studies should shed light on 
this apparent paradox.
Altogether, these findings highlight GSDMD as an attractive 
novel target to modulate pathological inflammation driven by pyro-
ptosis, including the release of inflammasome-dependent cytokines 
and DAMPs. While the current GSDMD tool compounds may still 
be a long way from the clinic, they may set the stage for the devel-
opment of selective GSDMD-targeted therapies by helping to shed 
light on the mechanisms that regulate GSDMD pore formation.
10  | AC TIVATING INFL AMMA SOME 
PATHWAYS IN C ANCER THER APY
As discussed above, results from CANTOS suggest that canaki-
numab-mediated blockage of IL-1β activity protects against the 
development of lung cancer, although the mechanism involved re-
mains unclear. However, IL-1β may have opposing roles in estab-
lished tumors.91 Evidence that IL-1β may have anti-tumor activity 
was first presented 30 years ago, when intraperitoneal injection of 
recombinant human IL-1β induced T-cell-dependent regression of 
subcutaneous SA1 sarcoma and L5178Y lymphomas in mice.161 The 
cancer-suppressive effect of IL-1β was confirmed in a mouse model 
for myeloma showing that IL-1β (as well as IL-1α) neutralization by 
anakinra severely impaired myeloma clearance by tumor-specific 
Th1 cells and tumor-infiltrating macrophages.162 Additionally, IL-1β 
release from dendritic cells was shown to be essential for priming of 
interferon gamma (IFNγ)-producing CD8+ T cells and elimination of 
tumor cells.163
Researchers are also investigating whether inflammasome ac-
tivation and the induction of pyroptosis upstream of IL-1β release 
can help render tumors more sensitive to therapy. Inhibitors of im-
mune checkpoint modulators such as programmed death 1 (PD-1) 
and cytotoxic T-lymphocyte antigen 4 (CTLA-4) invigorate CD8+ T 
cell-mediated killing of tumor cells and are revolutionizing immuno-
therapy of cancer. However, only a minority of patients responds 
to checkpoint blockade due to a lack of CD8+ T-cells in the tumor 
microenvironment. Researchers are exploring combination thera-
pies that facilitate CD8+ T-cell intratumoral infiltration in order to 
sensitize tumors to checkpoint therapy. In line with this strategy, 
an investigational phase I clinical trial in patients with solid cancers 
has recently been initiated with the NLRP3 agonist BMS-986299 
to study its therapeutic potential as a pyroptosis-stimulating com-
pound alone or when dosed to patients in combination with the 
checkpoint inhibitors Nivolumab and Ipilimumab (ClinicalTrials.gov 
Identifier: NCT03444753) (Figure 3).
Another clinical study aims to clarify the therapeutic effect 
of pyroptosis induction through the NLRP1 inflammasome in pa-
tients diagnosed with acute myeloid leukemia (AML), a heteroge-
nous hematological malignancy driven by uncontrolled expansion 
of myeloid progenitor cells in bone marrow and in circulation. This 
study centers on the experimental broad-spectrum DPP inhibitor 
BXCL701 (also named VbP, PT-100, or Talabostat) that was recently 
assigned orphan drug designation for the treatment of AML by the 
FDA, and is based on recent findings showing that VbP/BXCL701 
and more selective DPP8/DPP9 inhibitors are potent inducers 
of pyroptosis in AML cell lines and in primary AML samples from 
patients.164
Several recent studies showed that enforced activation of 
Gasdermin family members in cancer cells enhanced immune 
cell-mediated tumor clearance in mouse models,165-167 adding cre-
dence to the notion that pyroptosis induction may enhance cancer 
immunotherapies to the benefit of patients.
11  | CONCLUDING REMARKS
It has now become evident that inflammasomes play a crucial role in 
the immune response during microbial infections and non-infectious 
diseases. A wealth of information regarding the complexity of in-
flammasome signaling and their roles in diseases has emerged during 
the past two decades. This has spurred interest in translating basic 
research findings into potential novel therapies for inflammasome-
driven autoinflammatory diseases. Moreover, intriguing findings 
from the CANTOS trial suggest that inflammasomes may contribute 
importantly to cardiovascular risk in atherosclerosis patients and to 
the development of lung cancer. Without doubt, the ongoing devel-
opment of clinical inflammasome agonists and inhibitors will help 
tremendously to gain further insights into inflammasome-driven 
autoinflammatory pathologies in the future and may expand treat-
ment options for patients suffering from a host of common diseases 
with high unmet need, including metabolic and neurodegenerative 
diseases as well as certain cancers.
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